feed,title,long_url,short_url
Benzinga,Clovis Oncology's Flagship Ovarian Cancer Drug Improves Progression-Free Survival As First-Line Maintenance,https://benzinga.com/general/biotech/22/09/28828444/clovis-oncologys-flagship-ovarian-cancer-drug-improves-progression-free-survival-as-first-line-ma,https://bit.ly/3Qv6lAQ
Benzinga,"BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors",https://benzinga.com/general/biotech/22/09/28828435/beigenes-tislelizumab-shows-non-inferiority-in-overall-survival-safety-vs-standard-treatment-in-s,https://bit.ly/3xhyyEu
